GO:1905454 negative regulation of myeloid progenitor cell differentiation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905454 describes any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid progenitor cell differentiation.
• This biological process is essential for balancing hematopoietic stem and progenitor cell (HSPC) self-renewal with the production of mature myeloid cells.
• Key negative regulators include transcription factors such as RUNX1T1 and ear-2, epigenetic modifiers like METTL14, and microRNAs such as miR-223.
• Dysregulation of this process is a hallmark of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of specific genes in this process.
• Understanding GO:1905454 provides a foundation for developing differentiation therapies that force leukemic blasts to mature.
Description
Myeloid progenitor cell differentiation is the process by which hematopoietic stem and progenitor cells give rise to mature myeloid cells such as granulocytes, monocytes, and macrophages. This process is tightly controlled by a network of transcription factors, epigenetic regulators, and signaling pathways that ensure adequate production of immune cells while preventing excessive or premature differentiation. The Gene Ontology term GO:1905454, negative regulation of myeloid progenitor cell differentiation, captures the biological processes that inhibit or reduce the rate of this differentiation. Understanding these negative regulatory mechanisms is critical because their disruption can lead to bone marrow failure or hematological malignancies. Research into GO:1905454 has revealed that it is not a single pathway but a convergence of multiple molecular mechanisms, including transcriptional repression, microRNA-mediated silencing, and post-translational modifications. For example, the transcription factor RUNX1T1 (also known as ETO) can block granulocytic differentiation by repressing genes required for maturation. Similarly, the m6A RNA methyltransferase METTL14 inhibits HSPC differentiation and promotes leukemogenesis. These findings underscore the importance of negative regulation in maintaining the delicate balance between stem cell self-renewal and lineage commitment. For researchers, GO:1905454 provides a conceptual framework to study how specific genes and pathways contribute to myeloid differentiation blockade, a common feature of myeloid leukemias. By leveraging CRISPR gene editing and functional genomics, it is now possible to systematically test the role of candidate negative regulators in physiologically relevant models. This article synthesizes current knowledge on the mechanisms, key genes, and experimental approaches for studying negative regulation of myeloid progenitor cell differentiation.
negative regulation of myeloid progenitor cell differentiation At A Glance
| GO ID | GO:1905454 |
|---|---|
| GO term | negative regulation of myeloid progenitor cell differentiation |
| Ontology | biological_process |
| Synonym | down regulation of myeloid progenitor cell differentiation; down-regulation of myeloid progenitor cell differentiation; downregulation of myeloid progenitor cell differentiation; inhibition of myeloid progenitor cell differentiation |
| Major function | Inhibits or reduces the rate of differentiation of myeloid progenitor cells into mature myeloid cells |
| Related processes | Regulation of hematopoiesis, myeloid cell homeostasis, leukemogenesis |
| Key regulators | Transcription factors (RUNX1T1, ear-2), epigenetic modifiers (METTL14), microRNAs (miR-223), phosphatases (SHP-1) |
| Disease relevance | Acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms |
What Is GO:1905454?
According to the Gene Ontology, GO:1905454 (negative regulation of myeloid progenitor cell differentiation) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid progenitor cell differentiation. This term encompasses molecular events that inhibit the transition of myeloid progenitor cells into more mature myeloid cell types. It is a biological process and includes synonyms such as down regulation of myeloid progenitor cell differentiation, down-regulation of myeloid progenitor cell differentiation, downregulation of myeloid progenitor cell differentiation, and inhibition of myeloid progenitor cell differentiation.
Why Is negative regulation of myeloid progenitor cell differentiation Important in Cell Biology?
Negative regulation of myeloid progenitor cell differentiation is essential for maintaining the hematopoietic stem cell pool and preventing premature depletion of progenitors. It ensures that differentiation occurs only when needed, such as during infection or stress. Dysregulation of this process can lead to an accumulation of immature myeloid cells, a hallmark of acute myeloid leukemia (AML) and other myeloid malignancies. Therefore, understanding the molecular players that enforce this negative regulation is critical for developing targeted therapies that promote differentiation of leukemic cells.
• Maintains the balance between hematopoietic stem cell self-renewal and differentiation.
• Prevents premature exhaustion of myeloid progenitor pools.
• Its dysregulation is a key mechanism in acute myeloid leukemia (AML) pathogenesis.
• Provides targets for differentiation therapy, such as forcing leukemic blasts to mature.
• Involved in normal immune cell homeostasis and response to infection.
• Epigenetic regulators like METTL14 link RNA modification to differentiation blockade.
• MicroRNAs such as miR-223 fine-tune granulocyte production and function.
• Transcription factors like RUNX1T1 and ear-2 repress differentiation-associated genes.
• Phosphatases like SHP-1 modulate cytokine signaling to inhibit myeloid proliferation and function.
• p53 activity influences hematopoietic stem cell quiescence and differentiation.
What Happens During negative regulation of myeloid progenitor cell differentiation?
Transcriptional Repression of Differentiation Genes
In simple terms: Certain proteins act as brakes on the genes that would otherwise push progenitor cells to mature.
Negative regulation often begins at the level of transcription, where repressor proteins bind to regulatory elements of genes required for myeloid differentiation and inhibit their expression. For example, the RUNX1T1 (ETO) protein, a transcriptional corepressor, blocks granulocytic differentiation by recruiting histone deacetylases to target genes. Similarly, ear-2, a mammalian homolog of Drosophila seven-up, represses genes necessary for granulocytic differentiation in the 32Dcl3 myeloid precursor cell line. These transcriptional repressors maintain progenitors in an undifferentiated state.
Epigenetic and RNA Modifications
In simple terms: Chemical marks on DNA-associated proteins or RNA can lock cells in an immature state.
Epigenetic mechanisms also enforce negative regulation. METTL14, a component of the m6A RNA methyltransferase complex, inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. This RNA modification alters the stability or translation of transcripts that drive differentiation, effectively putting a brake on maturation. Additionally, cell-state-specific enhancers can be epigenetically poised to repress differentiation programs in hematopoietic stem cells.
MicroRNA-Mediated Silencing
In simple terms: Small RNA molecules can fine-tune the production of proteins needed for differentiation.
MicroRNAs (miRNAs) are key negative regulators of myeloid differentiation. miR-223, for instance, regulates progenitor cell proliferation and granulocyte function by targeting factors that promote differentiation. Its expression is tightly controlled during granulopoiesis, and its dysregulation can lead to excessive or impaired granulocyte production. Other miRNAs may similarly dampen the differentiation program by repressing transcription factors or signaling molecules.
Signaling Pathways That Inhibit Differentiation
In simple terms: External signals can tell progenitor cells to stay immature rather than mature.
Cytokine and growth factor signaling pathways can actively inhibit differentiation. The SH2 domain-containing tyrosine phosphatase SHP-1 negatively regulates myeloid cell proliferation and function, thereby influencing differentiation decisions. SHP-1 dampens signals from cytokine receptors, which can prevent progenitor cells from receiving the cues needed to differentiate. Additionally, p53 activity modulates hematopoietic stem cell quiescence and differentiation in response to stress, often acting to preserve the stem cell pool.
Protein Degradation and Post-Translational Control
In simple terms: Proteins that promote differentiation can be marked for destruction or kept inactive.
Post-translational modifications and protein degradation contribute to negative regulation. For example, Proteinase 3 (PRTN3) depletion attenuates leukemia by promoting myeloid differentiation, suggesting that PRTN3 normally helps maintain an undifferentiated state. The precise mechanisms may involve proteolytic processing of differentiation factors or modulation of signaling proteins. These layers of control ensure that differentiation is suppressed until the appropriate developmental or environmental signals override the block.
Key Genes Involved in GO:1905454 negative regulation of myeloid progenitor cell differentiation
The following genes and proteins have been experimentally implicated in the negative regulation of myeloid progenitor cell differentiation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUNX1T1 (ETO) | Transcriptional corepressor that blocks granulocytic differentiation | Fusion with RUNX1 in t(8;21) AML; target for differentiation therapy |
| METTL14 | m6A RNA methyltransferase; inhibits HSPC differentiation and promotes leukemogenesis | Epigenetic regulator; potential therapeutic target in AML |
| miR-223 | MicroRNA that regulates progenitor proliferation and granulocyte function | Fine-tunes granulopoiesis; dysregulated in myeloid malignancies |
| ear-2 (NR2F6) | Transcription factor that represses granulocytic differentiation | Mammalian homolog of Drosophila seven-up; model for differentiation blockade |
| SHP-1 (PTPN6) | Tyrosine phosphatase that negatively regulates myeloid proliferation and function | Modulates cytokine signaling; involved in immune regulation |
| p53 (TP53) | Tumor suppressor that regulates hematopoietic stem cell quiescence and differentiation | Stress response; mutations affect myeloid differentiation |
| PRTN3 | Proteinase 3; its depletion promotes myeloid differentiation | Potential target for differentiation therapy in leukemia |
| AML1/ETO | Chimeric leukemogenic fusion protein that inhibits differentiation | Oncogenic driver in t(8;21) AML |
| CEBPA | Transcription factor required for granulocytic differentiation; often repressed | Mutations in AML; target of negative regulators |
| SPI1 (PU.1) | Master regulator of myeloid differentiation; can be inhibited | Lineage commitment; modulated by enhancer activity |
| GATA2 | Transcription factor involved in stem cell maintenance; opposes differentiation | Regulates HSPC enhancers; implicated in leukemia |
| GFI1 | Transcriptional repressor that inhibits granulocytic differentiation | Recruited by RUNX1T1; therapeutic target |
| HDACs | Histone deacetylases recruited by repressors to silence differentiation genes | Targets of HDAC inhibitors in AML |
| DNMT3A | DNA methyltransferase that can repress differentiation genes | Epigenetic modifier; mutated in hematologic malignancies |
| ASXL1 | Chromatin modifier that influences myeloid differentiation | Frequently mutated in myeloid neoplasms |
| EZH2 | Polycomb repressive complex 2 subunit; silences differentiation genes | Epigenetic regulator; target in lymphoma and leukemia |
| JAK2 | Kinase that can drive proliferation and block differentiation | Mutated in myeloproliferative neoplasms |
| STAT3 | Transcription factor activated by cytokines; can inhibit differentiation | Downstream of JAK2; target for inhibitors |
How Is negative regulation of myeloid progenitor cell differentiation Regulated?
The negative regulation of myeloid progenitor cell differentiation is itself subject to multiple layers of control. Upstream signaling pathways, such as those involving JAK2/STAT3, can induce the expression of transcriptional repressors like RUNX1T1 or ear-2. Epigenetic modifiers, including METTL14 and EZH2, establish and maintain repressive chromatin states that silence differentiation genes. MicroRNAs such as miR-223 provide post-transcriptional fine-tuning, ensuring that differentiation is not prematurely activated. Additionally, stress-responsive pathways involving p53 can transiently enforce quiescence and inhibit differentiation under conditions of cellular stress. This regulatory network allows hematopoietic progenitors to integrate developmental and environmental cues to decide whether to differentiate or remain immature.
negative regulation of myeloid progenitor cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RUNX1T1 (ETO) | Acute myeloid leukemia (t(8;21)) | Knockout or overexpression in AML cell lines (e.g., Kasumi-1); patient-derived xenografts |
| METTL14 | Acute myeloid leukemia; myelodysplastic syndromes | Conditional knockout in mouse HSPCs; CRISPR knockout in human leukemia cell lines |
| miR-223 | Myeloid malignancies; inflammatory diseases | miR-223 knockout mice; overexpression in hematopoietic stem cells |
| SHP-1 (PTPN6) | Myeloproliferative neoplasms; immune dysregulation | SHP-1 deficient mice; knockdown in myeloid cell lines |
| p53 (TP53) | Myelodysplastic syndromes; acute myeloid leukemia | p53 knockout mice; CRISPR knockout in human CD34+ cells |
Acute Myeloid Leukemia (AML)
AML is characterized by the accumulation of immature myeloid blasts due to a block in differentiation. Negative regulators of myeloid progenitor cell differentiation are often dysregulated in AML. For example, the RUNX1T1-ETO fusion protein, resulting from t(8;21), recruits corepressors to block granulocytic differentiation. METTL14 overexpression inhibits HSPC differentiation and promotes leukemogenesis through m6A modification. Targeting these negative regulators, for instance by depleting PRTN3, can restore differentiation and attenuate leukemia in experimental models. Thus, understanding GO:1905454 provides a rationale for differentiation therapy in AML.
Myelodysplastic Syndromes (MDS)
MDS are clonal disorders characterized by ineffective hematopoiesis and a high risk of progression to AML. Dysregulation of negative regulators can contribute to the differentiation block seen in MDS. For instance, mutations in epigenetic modifiers such as ASXL1 or EZH2 can alter the expression of genes that inhibit differentiation. The p53 pathway, which regulates stem cell quiescence, is often perturbed in MDS with complex karyotypes. Restoring normal differentiation by modulating these negative regulators is a potential therapeutic strategy.
Myeloproliferative Neoplasms (MPN)
MPNs such as polycythemia vera and essential thrombocythemia are driven by mutations that enhance proliferation and can inhibit differentiation. The JAK2 V617F mutation, for example, activates signaling pathways that may suppress differentiation programs. SHP-1, a negative regulator of cytokine signaling, can modulate this process, and its dysfunction may contribute to MPN pathogenesis. Understanding how negative regulation is subverted in MPN could lead to new treatments.
Infections and Immune Dysregulation
Negative regulation of myeloid differentiation is also important during immune responses. miR-223, which regulates granulocyte function, is critical for controlling inflammation and preventing excessive neutrophil activation. Dysregulation of such negative regulators can lead to immune pathology, including chronic inflammation or increased susceptibility to infections. Thus, GO:1905454 has implications beyond cancer, impacting normal immune homeostasis.
From negative regulation of myeloid progenitor cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene promote myeloid differentiation? | CRISPR knockout in human myeloid cell lines (e.g., HL-60, U937) or primary CD34+ cells |
| Does a specific point mutation in a negative regulator alter its function? | CRISPR point mutation (e.g., knock-in of kinase-dead or constitutive-active alleles) in hematopoietic cells |
| Does overexpression of a negative regulator block differentiation? | CRISPR knock-in of a doxycycline-inducible overexpression cassette at a safe harbor locus |
| How does a negative regulator affect chromatin state? | CRISPR knockout followed by ATAC-seq or ChIP-seq in primary AML cells |
| Can differentiation therapy overcome the block? | Patient-derived xenografts treated with differentiation-inducing agents (e.g., ATRA, PRTN3 inhibitors) |
| What is the role of a microRNA in differentiation? | CRISPR knockout or overexpression of miR-223 in mouse HSPCs followed by transplantation |
How to Study the negative regulation of myeloid progenitor cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify differentiation-associated transcripts upon knockout of a negative regulator |
| ChIP-seq | Genome-wide binding of transcription factors | Map RUNX1T1 or ear-2 binding sites in myeloid cells |
| ATAC-seq | Chromatin accessibility | Assess how negative regulators alter enhancer/promoter accessibility |
| CRISPR knockout screen | Phenotypic effects of gene loss | Discover novel negative regulators of differentiation |
| Phosphoproteomics | Phosphorylation status of signaling proteins | Measure SHP-1-mediated dephosphorylation events |
| Flow cytometry | Cell surface markers of differentiation | Quantify CD11b or Gr-1 expression after gene perturbation |
| Colony-forming unit (CFU) assay | Progenitor differentiation potential | Evaluate myeloid differentiation capacity in vitro |
| Xenograft transplantation | In vivo differentiation and leukemogenesis | Test the impact of negative regulators on leukemia development |
Transcriptomic Profiling (RNA-seq)
RNA sequencing is widely used to identify genes and pathways that are differentially expressed upon modulation of negative regulators. For example, RNA-seq of METTL14-knockout HSPCs revealed changes in transcripts involved in differentiation. Similarly, RNA-seq can uncover the transcriptional consequences of RUNX1T1 repression. This method provides a global view of how negative regulators shape the differentiation transcriptome.
Epigenomic Mapping (ChIP-seq, ATAC-seq)
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) can map the binding sites of transcriptional repressors like RUNX1T1 or ear-2 across the genome. ATAC-seq measures chromatin accessibility and can reveal how negative regulators alter the epigenetic landscape to block differentiation. These techniques are essential for understanding the cis-regulatory logic of differentiation blockade.
Functional Genomics (CRISPR Screens)
Pooled CRISPR knockout screens enable unbiased discovery of genes that negatively regulate myeloid differentiation. For instance, a genome-wide screen in a myeloid cell line could identify knockouts that induce differentiation. Such screens have the power to uncover novel regulators and validate known ones like METTL14 or PRTN3. This approach is highly scalable and can be performed in primary cells.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and post-translational modifications upon perturbation of negative regulators. For example, SHP-1 phosphatase activity affects tyrosine phosphorylation of signaling proteins. Phosphoproteomics can reveal how negative regulators modulate signaling cascades that control differentiation. This method complements transcriptomic data by capturing post-transcriptional effects.
How CRISPR Can Be Used to Study GO:1905454 negative regulation of myeloid progenitor cell differentiation
Knockout
CRISPR knockout is used to delete a candidate negative regulator and assess whether loss of function promotes myeloid differentiation. For example, knocking out METTL14 in human leukemia cells can lead to increased differentiation and reduced leukemogenic potential. Similarly, PRTN3 knockout attenuates leukemia by promoting myeloid differentiation. Knockout models are essential for establishing causality.
Point Mutation
CRISPR point mutation allows the introduction of specific amino acid changes to dissect domain functions. For instance, mutating the catalytic residue of METTL14 or the DNA-binding domain of RUNX1T1 can reveal which activities are required for differentiation blockade. This approach is more precise than knockout and can mimic patient mutations.
Knock-in
Knock-in of reporter genes or epitope tags enables tracking of negative regulator expression and localization. For example, knocking in a fluorescent tag at the endogenous RUNX1T1 locus allows live-cell imaging of its dynamics during differentiation. Knock-in of inducible overexpression cassettes can also be used to study gain-of-function effects.
Overexpression
CRISPR activation (CRISPRa) or knock-in of a strong promoter can drive overexpression of a negative regulator to test whether it is sufficient to block differentiation. Overexpressing miR-223 in hematopoietic progenitors, for example, can impair granulocyte function. Overexpression models are useful for identifying downstream targets and for validating therapeutic hypotheses.
How EDITGENE Supports negative regulation of myeloid progenitor cell differentiation Research
Researchers studying negative regulation of myeloid progenitor cell differentiation-related genes often need to determine whether a candidate gene is causally involved in the differentiation block. This requires precise genetic manipulation in relevant cellular models, followed by functional assays. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of myeloid progenitor cell differentiation research.
Frequently Asked Questions About negative regulation of myeloid progenitor cell differentiation
What is negative regulation of myeloid progenitor cell differentiation?
It is a biological process (GO:1905454) that stops, prevents, or reduces the rate of differentiation of myeloid progenitor cells into mature myeloid cells.
What genes are involved in negative regulation of myeloid progenitor cell differentiation?
Key genes include RUNX1T1, METTL14, miR-223, ear-2, SHP-1, and PRTN3, among others.
How does METTL14 inhibit myeloid differentiation?
METTL14 is an m6A RNA methyltransferase that modifies mRNAs of differentiation-associated genes, reducing their stability or translation, thereby blocking differentiation.
What is the role of miR-223 in myeloid differentiation?
miR-223 regulates progenitor cell proliferation and granulocyte function by repressing target genes, thus fine-tuning differentiation.
Which diseases are associated with dysregulation of this process?
Acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms are linked to defects in negative regulation of myeloid differentiation.
How can CRISPR be used to study negative regulators of myeloid differentiation?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of candidate genes in differentiation blockade.
What experimental models are suitable for studying GO:1905454?
Myeloid cell lines (e.g., HL-60, U937), primary CD34+ cells, and mouse HSPCs are commonly used, along with xenograft models.
What is the connection between RUNX1T1 and myeloid differentiation?
RUNX1T1 (ETO) is a transcriptional corepressor that blocks granulocytic differentiation and is implicated in t(8;21) AML.
How does SHP-1 regulate myeloid cells?
SHP-1 is a tyrosine phosphatase that negatively regulates myeloid cell proliferation and function by dampening cytokine signaling.
What methods are used to study negative regulation of myeloid differentiation?
RNA-seq, ChIP-seq, ATAC-seq, CRISPR screens, proteomics, and flow cytometry are key methods.
Conclusion
Negative regulation of myeloid progenitor cell differentiation (GO:1905454) is a critical biological process that maintains hematopoietic homeostasis and prevents premature differentiation. Its dysregulation is central to the pathogenesis of myeloid malignancies such as AML and MDS. Key regulators include transcription factors, epigenetic modifiers, microRNAs, and signaling phosphatases. Advances in CRISPR gene editing now allow researchers to systematically dissect these mechanisms and identify new therapeutic targets. Continued investigation of GO:1905454 promises to yield novel differentiation therapies for hematologic diseases.
References
- 1. Frömel R et al.. 2025. Design principles of cell-state-specific enhancers in hematopoiesis.. Cell 188(12):3202-3218.e21 PMID: 40345201
- 2. Weng H et al.. 2018. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.. Cell Stem Cell 22(2):191-205.e9 PMID: 29290617
- 3. Hu N et al.. 2022. RUNX1T1 function in cell fate.. Stem Cell Res Ther 13(1):369 PMID: 35902872
- 4. Liu H et al.. 2024. Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation.. Cell Death Differ 31(6):697-710 PMID: 38589495
- 5. Ahn MY et al.. 1998. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO.. Proc Natl Acad Sci U S A 95(4):1812-7 PMID: 9465099
- 6. Dong Q et al.. 1999. Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1.. J Immunol 162(6):3220-30 PMID: 10092773
- 7. Barajas S et al.. 2022. Role of p53 in regulation of hematopoiesis in health and disease.. Curr Opin Hematol 29(4):194-200 PMID: 35787548
- 8. Johnnidis JB et al.. 2008. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223.. Nature 451(7182):1125-9 PMID: 18278031
